Methyl 4-(Bromomethyl)-3-Methoxybenzoate CAS 70264-94-7 Zafirlukast Intermediate
Manufacturer Supply, High Purity, Commercial Production
Chemical Name: Methyl 4-(Bromomethyl)-3-Methoxybenzoate
CAS: 70264-94-7
| Chemical Name | Methyl 4-(Bromomethyl)-3-Methoxybenzoate |
| Synonyms | 4-(Bromomethyl)-3-methoxybenzoic Acid Methyl Ester; Methyl 4-(Bromomethyl)-m-anisate; 4-(Bromomethyl)-m-anisic Acid Methyl Ester |
| CAS Number | 70264-94-7 |
| CAT Number | RF-PI437 |
| Stock Status | In Stock |
| Molecular Formula | C10H11BrO3 |
| Molecular Weight | 259.10 |
| Melting Point | 92.0 to 94.0℃ |
| Density | 1.432 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | Pale Yellow Powder |
| Assay / Analysis Method | ≥98.0% (HPLC) |
| Loss on Drying | ≤1.0% |
| Residue on Ignition | ≤0.50% |
| Total Impurities | ≤2.0% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Zafirlukast (CAS: 107753-78-6), Used as an antiasthmatic |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Methyl 4-(Bromomethyl)-3-Methoxybenzoate (CAS 70264-94-7) is used as an intermediate of Zafirlukast (CAS: 107753-78-6). Zafirlukast is a highly selective and long-acting oral lys-LTs antagonist. Leukotrienes play an important role in the pathogenesis of asthma. These substances are peptides, being capable of selectively binding to LTC4, LTD4 and LTE4 receptor for antagonism of its effect, reducing the symptoms of asthma and improving lung function. This product is both a preventive agent of inflammation caused by asthma (being antagonistic to leukotriene proinflammatory activity) and a relief drug for bronchial asthma (be antagonistic to leukotriene induced bronchial smooth muscle contraction). The use of this product does not change the smooth muscle response to β2 receptors and has good efficacy in the treatment of bronchoconstriction caused by antigen, aspirin, exercise and cold air, being able to reduce the dosage of hormone and β2 receptor agonist.
